Paper Details

  1. Home
  2. Paper Details

Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.

Author: BahtaMeriam, CowartJulie, CultraroConstance M, GaoShaojian, GuhaUdayan, KeswaniMeghana, KirkaliFatos, MaityTapan K, NguyenKhoa Dang P, PittsStephanie, QiYue, RossKaren E, WuCathy, ZhangXu

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the proteomic and phosphoproteomic changes in lung cancer cells resistant to third-generation EGFR TKIs, like osimertinib. It found that inhibiting SHP2 phosphatase could lead to resistance and identified dactolisib, a PI3K/mTOR inhibitor, as a potential combination therapy to overcome this resistance.
Paper Details　
Original Abstract of the Article :
Lung cancer is the leading cause of cancer mortality worldwide. The treatment of patients with lung cancer harboring mutant EGFR with orally administered EGFR tyrosine kinase inhibitors (TKI) has been a paradigm shift. Osimertinib and rociletinib are third-generation irreversible EGFR TKIs targeting...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/33727228

データ提供：米国国立医学図書館（NLM）

Conquering Resistance in Lung Cancer Treatment

Lung cancer is a formidable opponent, and resistance to EGFR tyrosine kinase inhibitors (TKIs) is a major challenge in its treatment. It's like a desert storm, relentlessly challenging even the most effective defenses. This study investigates the mechanisms behind TKI resistance and explores potential strategies to overcome it.

Proteomic Analysis Reveals New Insights

The researchers used proteomic analysis to identify changes in protein expression and phosphorylation in lung cancer cells that have become resistant to third-generation EGFR TKIs. This approach revealed important insights into the mechanisms underlying resistance, like mapping the shifting sand dunes of a desert to understand the forces that shape its landscape.

New Drug Targets for Overcoming Resistance

The study identified potential drug targets that could be used to overcome TKI resistance. The researchers found that combining osimertinib with the PI3K/MTOR inhibitor dactolisib effectively circumvented resistance both in vitro and in vivo. It's like finding a way to redirect a desert storm by strategically manipulating the wind patterns.

Dr.Camel's Conclusion

This study provides valuable insights into the complex mechanisms behind EGFR TKI resistance in lung cancer. The identification of new drug targets and the successful combination of osimertinib with dactolisib offer hope for overcoming this significant obstacle in lung cancer treatment. It's like finding a way to tame a desert storm, offering a more stable and predictable future for patients.

Date :
  1. Date Completed 2021-11-04
  2. Date Revised 2022-10-05
Further Info :

Pubmed ID

33727228

DOI: Digital Object Identifier

NIHMS1685146

Related Literature

Article Analysis
・Side Effects of osimertinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.